B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund lessened its position in Baxter International Inc (NYSE:BAX) by 55.7% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 7,950 shares of the medical instruments supplier’s stock after selling 9,992 shares during the period. B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund’s holdings in Baxter International were worth $587,000 as of its most recent filing with the SEC.
Several other large investors have also recently modified their holdings of the company. Bridgeworth LLC acquired a new position in Baxter International during the 2nd quarter worth about $102,000. Migdal Insurance & Financial Holdings Ltd. lifted its position in Baxter International by 3,088.9% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,435 shares of the medical instruments supplier’s stock worth $106,000 after buying an additional 1,390 shares in the last quarter. Baker Ellis Asset Management LLC acquired a new position in Baxter International during the 2nd quarter worth about $111,000. Centaurus Financial Inc. acquired a new position in Baxter International during the 2nd quarter worth about $117,000. Finally, Whittier Trust Co. of Nevada Inc. lifted its position in Baxter International by 84.4% during the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 1,748 shares of the medical instruments supplier’s stock worth $126,000 after buying an additional 800 shares in the last quarter. Institutional investors own 83.08% of the company’s stock.
NYSE:BAX traded down $0.85 on Monday, hitting $73.33. 2,903,800 shares of the stock were exchanged, compared to its average volume of 3,015,593. The stock has a market capitalization of $41.19 billion, a P/E ratio of 29.60, a P/E/G ratio of 2.08 and a beta of 0.77. Baxter International Inc has a 52 week low of $60.78 and a 52 week high of $78.38. The company has a current ratio of 2.62, a quick ratio of 2.00 and a debt-to-equity ratio of 0.39.
Baxter International (NYSE:BAX) last announced its quarterly earnings results on Thursday, July 26th. The medical instruments supplier reported $0.77 EPS for the quarter, beating analysts’ consensus estimates of $0.71 by $0.06. The company had revenue of $2.84 billion during the quarter, compared to analysts’ expectations of $2.83 billion. Baxter International had a return on equity of 16.63% and a net margin of 8.29%. Baxter International’s revenue was up 9.1% on a year-over-year basis. During the same period in the prior year, the business posted $0.63 EPS. As a group, equities analysts predict that Baxter International Inc will post 2.98 EPS for the current year.
The business also recently declared a quarterly dividend, which was paid on Monday, October 1st. Stockholders of record on Friday, August 31st were paid a $0.19 dividend. The ex-dividend date of this dividend was Thursday, August 30th. This represents a $0.76 dividend on an annualized basis and a dividend yield of 1.04%. Baxter International’s dividend payout ratio (DPR) is presently 30.65%.
Several research analysts recently issued reports on BAX shares. Argus reiterated a “hold” rating on shares of Baxter International in a research report on Tuesday, September 4th. Zacks Investment Research upgraded shares of Baxter International from a “hold” rating to a “buy” rating and set a $87.00 price target on the stock in a research report on Tuesday, September 25th. JPMorgan Chase & Co. upped their price target on shares of Baxter International from $80.00 to $85.00 and gave the stock an “overweight” rating in a research report on Friday, July 27th. Piper Jaffray Companies boosted their price objective on Baxter International from $77.00 to $83.00 and gave the stock an “overweight” rating in a report on Friday, July 27th. Finally, Royal Bank of Canada reissued a “hold” rating and set a $76.00 price objective on shares of Baxter International in a report on Friday, July 27th. Six research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $76.43.
In other news, SVP Giuseppe Accogli sold 17,647 shares of the company’s stock in a transaction dated Monday, September 17th. The stock was sold at an average price of $77.27, for a total value of $1,363,583.69. Following the completion of the sale, the senior vice president now directly owns 59,452 shares of the company’s stock, valued at approximately $4,593,856.04. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Carole J. Shapazian sold 5,400 shares of the company’s stock in a transaction dated Wednesday, August 8th. The shares were sold at an average price of $72.97, for a total value of $394,038.00. Following the completion of the sale, the director now directly owns 15,248 shares of the company’s stock, valued at $1,112,646.56. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 33,733 shares of company stock valued at $2,559,072. 0.07% of the stock is currently owned by company insiders.
Baxter International Profile
Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Featured Article: Stop Order Uses For Individual Investors
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.